Key Takeaways
- Singapore's Drew & Napier is set to file claims against the Swiss government, seeking approximately $300 million in compensation for 560 Asian bondholders impacted by the 2023 Credit Suisse AT1 debt wipeout, following a recent Swiss court ruling that deemed the write-down unlawful.
- AstraZeneca's (AZN) and Daiichi Sankyo's Datroway (datopotamab deruxtecan) has demonstrated a significant 5.0-month improvement in overall survival in aggressive triple-negative breast cancer (TNBC) patients, marking a historic milestone as the first therapy to achieve this against chemotherapy in a specific patient population.
- An EY study reveals a reversal in Germany's corporate landscape, with top female managers at the country's largest listed companies earning significantly less than their male counterparts in 2024, breaking a decade-long trend of narrowing the pay gap.
- Prominent historian and critic of Vladimir Putin, Karl Schlögel, is slated to receive the prestigious Peace Prize of the German Book Trade at the Frankfurt Book Fair today, October 19, 2025.
Legal Battle Intensifies for Credit Suisse AT1 Bondholders
Singapore's prominent law firm, Drew & Napier, is preparing to initiate investment treaty claims against the Swiss government by the close of 2025. The firm aims to secure compensation for hundreds of Asian bondholders of Credit Suisse (CSGN) Additional Tier 1 (AT1) debt, which was controversially wiped out in 2023 during the bank's rescue by UBS Group AG (UBSG). The claims, initially for Japanese bondholders, will extend to investors in Hong Kong and Singapore, representing approximately 560 bondholders seeking to recover an estimated $300 million in losses.
This legal action follows a pivotal Swiss court ruling that declared the write-down of Credit Suisse AT1 bonds unlawful, providing a significant boost to bondholders' efforts for redress. Drew & Napier had previously sent trigger letters to the Swiss government in December 2024 and May 2025, initiating the six-month negotiation period required under bilateral investment treaties.
AstraZeneca's Datroway Shows Significant Survival Benefit in Aggressive Breast Cancer
In a major advancement for oncology, AstraZeneca (AZN) and Daiichi Sankyo's TROP2-directed antibody-drug conjugate, Datroway (datopotamab deruxtecan), has demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) who are not candidates for immunotherapy.
Results from the Phase III TROPION-Breast02 trial, presented today at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, showed that Datroway extended median OS by 5.0 months compared to chemotherapy (23.7 months vs. 18.7 months). The therapy also achieved a 43% reduction in the risk of disease progression or death, establishing Datroway as the first and only treatment to significantly improve overall survival against chemotherapy in this challenging patient population.
German Female Executives See Pay Decline in 2024, Widening Gender Gap
A new study by consulting firm EY reveals a concerning trend in Germany's corporate landscape: top female managers at the nation's largest listed companies experienced a significant drop in earnings in 2024, falling behind their male colleagues. This marks a reversal of a long-standing trend that had seen the pay gap gradually narrow since 2014.
Salaries for women board members across the DAX, MDAX, and SDAX indices averaged EUR2.15 million (excluding CEO positions), an 11% decrease from the previous year. In contrast, their male counterparts saw a slight increase of 0.4%, reaching an average of EUR2.27 million. The disparity was particularly pronounced within the leading DAX index, where male board members' compensation rose to an average of EUR3.38 million, while top female executives' pay fell to EUR2.92 million, a difference of approximately half a million euros. EY attributes this shift to female board members no longer being a "rare species" and often entering with lower initial compensation, impacting the overall salary structure for women in leadership roles.
Historian Karl Schlögel to Receive Peace Prize
Today, at the Frankfurt Book Fair, renowned German historian Karl Schlögel is set to be awarded the prestigious Peace Prize of the German Book Trade. Schlögel, a vocal critic of Russian President Vladimir Putin, is being honored for his extensive body of work that has brought Eastern European environments to a wider audience and for his early warnings regarding Putin's aggressive expansionist policies. The award, accompanied by 25,000 euros, recognizes individuals who have made outstanding contributions to the idea of peace through their work in literature, science, or art.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.